| Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, ... Blood, The Journal of the American Society of Hematology 135 (11), 791-803, 2020 | 466 | 2020 |
| Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia DM Moujalled, G Pomilio, C Ghiurau, A Ivey, J Salmon, S Rijal, S Macraild, ... Leukemia 33 (4), 905-917, 2019 | 167 | 2019 |
| The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia G Brumatti, C Ma, N Lalaoui, NY Nguyen, M Navarro, MC Tanzer, ... Science translational medicine 8 (339), 339ra69-339ra69, 2016 | 162 | 2016 |
| Adult hematopoietic stem and progenitor cells require either Lyl1 or Scl for survival GP Souroullas, JM Salmon, F Sablitzky, DJ Curtis, MA Goodell Cell stem cell 4 (2), 180-186, 2009 | 154 | 2009 |
| Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy CC Chua, AW Roberts, J Reynolds, CY Fong, SB Ting, JM Salmon, ... Journal of Clinical Oncology 38 (30), 3506-3517, 2020 | 134 | 2020 |
| Differentiation therapy for the treatment of t (8; 21) acute myeloid leukemia using histone deacetylase inhibitors M Bots, I Verbrugge, BP Martin, JM Salmon, M Ghisi, A Baker, K Stanley, ... Blood, The Journal of the American Society of Hematology 123 (9), 1341-1352, 2014 | 129 | 2014 |
| Targeting p38 or MK2 enhances the anti-leukemic activity of Smac-mimetics N Lalaoui, K Hänggi, G Brumatti, D Chau, NYN Nguyen, L Vasilikos, ... Cancer cell 29 (2), 145-158, 2016 | 121 | 2016 |
| Interconversion between tumorigenic and differentiated states in acute myeloid leukemia MD McKenzie, M Ghisi, EP Oxley, S Ngo, L Cimmino, C Esnault, R Liu, ... Cell stem cell 25 (2), 258-272. e9, 2019 | 78 | 2019 |
| The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma A Newbold, JM Salmon, BP Martin, K Stanley, RW Johnstone Oncogene 33 (47), 5415-5423, 2014 | 65 | 2014 |
| Functional but abnormal adult erythropoiesis in the absence of the stem cell leukemia gene MA Hall, NJ Slater, CG Begley, JM Salmon, LJ Van Stekelenburg, ... Molecular and cellular biology, 2005 | 61 | 2005 |
| A critical role for the transcription factor Scl in platelet production during stress thrombopoiesis MP McCormack, MA Hall, SM Schoenwaelder, Q Zhao, S Ellis, ... Blood 108 (7), 2248-2256, 2006 | 57 | 2006 |
| Aberrant mast-cell differentiation in mice lacking the stem-cell leukemia gene JM Salmon, NJ Slater, MA Hall, MP McCormack, SL Nutt, SM Jane, ... Blood, The Journal of the American Society of Hematology 110 (10), 3573-3581, 2007 | 33 | 2007 |
| Concise review: blood relatives: formation and regulation of hematopoietic stem cells by the basic helix-loop-helix transcription factors stem cell leukemia and lymphoblastic … DJ Curtis, JM Salmon, JE Pimanda Stem Cells 30 (6), 1053-1058, 2012 | 31 | 2012 |
| Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells CS Tremblay, SK Chiu, J Saw, H McCalmont, V Litalien, J Boyle, ... Nature communications 11 (1), 6211, 2020 | 21 | 2020 |
| Molecular patterns of response and outcome in the chemotherapy and venetoclax in elderly AML trial (CAVEAT study) AH Wei, CC Chua, S Tiong, CY Fong, SB Ting, S Macraild, JM Salmon, ... Blood 132, 333, 2018 | 19 | 2018 |
| Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t (8; 21) acute myeloid … JM Salmon, M Bots, E Vidacs, KL Stanley, P Atadja, J Zuber, ... Clinical epigenetics 7, 1-7, 2015 | 13 | 2015 |
| Epigenetic activation of plasmacytoid DCs drives IFNAR-dependent therapeutic differentiation of AML JM Salmon, I Todorovski, KL Stanley, C Bruedigam, CJ Kearney, ... Cancer Discovery 12 (6), 1560-1579, 2022 | 12 | 2022 |
| Anti-leukemic activity of single agent venetoclax in newly diagnosed acute myeloid leukemia: A sub-set analysis of the CAVEAT study CC Chua, J Reynolds, JM Salmon, C Fong, SB Ting, S Tiong, S Fleming, ... Blood 134, 462, 2019 | 7 | 2019 |
| Combined BCL-2 and HDAC targeting has potent and TP53 independent activity in AML JM Salmon, G Pomilio, DM Moujalled, S MacRaild, CE Teh, S Riajl, A Ivey, ... Blood 132, 1426, 2018 | 5 | 2018 |
| Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit JM Salmon, I Todorovski, SJ Vervoort, KL Stanley, CJ Kearney, ... bioRxiv, 2020.08. 23.235499, 2020 | 2 | 2020 |
Professor Stephen JaneMonash UniversityVerified email at monash.edu
